Omalizumab (Xolair) as an adjunct therapy

Type: drug

Status: FDA Approved (for asthma), Investigational (for ABPA)

Developer: Genentech, Novartis

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026